These properties have made BPC-157 a subject of interest in studies on inflammatory bowel disease, traumatic brain injury, and neural regeneration research
In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings
Importantly, these results are observational and should not be interpreted as medical or exercise advice
Benefits of Semaglutide Supports lower blood pressure: Clinical studies show semaglutide can contribute to reductions in hypertension
The FDA has long turned a wary eye to the supplement industrys unverified claims but stopped short of serious reform
MASH resolution: The trial measured this at 52 weeks